These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 18715136)

  • 1. Bisphosphonate therapy ameliorates hearing loss in mice lacking osteoprotegerin.
    Kanzaki S; Takada Y; Ogawa K; Matsuo K
    J Bone Miner Res; 2009 Jan; 24(1):43-9. PubMed ID: 18715136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resorption of auditory ossicles and hearing loss in mice lacking osteoprotegerin.
    Kanzaki S; Ito M; Takada Y; Ogawa K; Matsuo K
    Bone; 2006 Aug; 39(2):414-9. PubMed ID: 16564235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical treatment of otosclerosis: rationale for use of bisphosphonates.
    Brookler K
    Int Tinnitus J; 2008; 14(2):92-6. PubMed ID: 19205157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegrin knockout mice demonstrate abnormal remodeling of the otic capsule and progressive hearing loss.
    Zehnder AF; Kristiansen AG; Adams JC; Kujawa SG; Merchant SN; McKenna MJ
    Laryngoscope; 2006 Feb; 116(2):201-6. PubMed ID: 16467704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of sex hormones on bone metabolism of the otic capsule--an overview.
    Horner KC
    Hear Res; 2009 Jun; 252(1-2):56-60. PubMed ID: 19121641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.
    Martini G; Gennari L; Merlotti D; Salvadori S; Franci MB; Campagna S; Avanzati A; De Paola V; Valleggi F; Nuti R
    Bone; 2007 Feb; 40(2):457-63. PubMed ID: 16979395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.
    Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Koukoulis G; Kita M; Avramidis A
    Horm Metab Res; 2008 Apr; 40(4):281-5. PubMed ID: 18275008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule.
    Zehnder AF; Kristiansen AG; Adams JC; Merchant SN; McKenna MJ
    Laryngoscope; 2005 Jan; 115(1):172-7. PubMed ID: 15630389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women.
    D'Amelio P; Grimaldi A; Di Bella S; Tamone C; Brianza SZ; Ravazzoli MG; Bernabei P; Cristofaro MA; Pescarmona GP; Isaia G
    J Bone Miner Res; 2008 Mar; 23(3):373-9. PubMed ID: 17967134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Ca
    Cao C; Oswald AB; Fabella BA; Ren Y; Rodriguiz R; Trainor G; Greenblatt MB; Hilton MJ; Pitt GS
    Bone; 2019 Aug; 125():160-168. PubMed ID: 31121355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
    Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
    Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment.
    Mossetti G; Rendina D; De Filippo G; Viceconti R; Di Domenico G; Cioffi M; Postiglione L; Nunziata V
    Bone; 2005 Mar; 36(3):549-54. PubMed ID: 15777635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.
    Zheng Y; Zhou H; Brennan K; Blair JM; Modzelewski JR; Seibel MJ; Dunstan CR
    Bone; 2007 Feb; 40(2):471-8. PubMed ID: 17092788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection and differentiation of sensorineural hearing loss in mice using auditory steady-state responses and transient auditory brainstem responses.
    Pauli-Magnus D; Hoch G; Strenzke N; Anderson S; Jentsch TJ; Moser T
    Neuroscience; 2007 Nov; 149(3):673-84. PubMed ID: 17869440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of OPG in regulation of bone remodeling].
    Nakamichi Y; Udagawa N
    Clin Calcium; 2006 Sep; 16(9):1463-68. PubMed ID: 16951469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Juvenile Paget's disease: the second reported, oldest patient is homozygous for the TNFRSF11B "Balkan" mutation (966_969delTGACinsCTT), which elevates circulating immunoreactive osteoprotegerin levels.
    Whyte MP; Singhellakis PN; Petersen MB; Davies M; Totty WG; Mumm S
    J Bone Miner Res; 2007 Jun; 22(6):938-46. PubMed ID: 17352649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.
    Schett G; Redlich K; Hayer S; Zwerina J; Bolon B; Dunstan C; Görtz B; Schulz A; Bergmeister H; Kollias G; Steiner G; Smolen JS
    Arthritis Rheum; 2003 Jul; 48(7):2042-51. PubMed ID: 12847699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired vibration of auditory ossicles in osteopetrotic mice.
    Kanzaki S; Takada Y; Niida S; Takeda Y; Udagawa N; Ogawa K; Nango N; Momose A; Matsuo K
    Am J Pathol; 2011 Mar; 178(3):1270-8. PubMed ID: 21356377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the biology of the bony otic capsule and the pathogenesis of otosclerosis.
    Bloch SL
    Dan Med J; 2012 Oct; 59(10):B4524. PubMed ID: 23158898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.